Skip to content
Catalyst
Search

Papers/PMID:40552569

Silymarin for adults with metabolic dysfunction-associated steatotic liver disease.

The Cochrane database of systematic reviews2025The record

3 findings · 1 compound · 3 endpoints · 1 null

What it reported

How to read these marks

What moved

2 findings

  • milk thistle extract (silymarin) — decreases gamma-glutamyl transferase

    Evidence strength: very limited.Finding
    “Silymarin monotherapy versus no intervention or placebo may decrease ALT (MD -7.21 U/L, 95% CI -10.62 to -3.80; 6 trials, 409 participants; very low-certainty evidence) and GGT (MD -8.30 U/L, 95% CI -12.43 to -4.17; 1 trial, 45 participants; very low-certainty evidence), but the evidence is very uncertain.”
    Quoted verbatim from Silymarin for adults with metabolic dysfunction-associated steatotic liver disease..
    Study
    meta-analysis
    Participants
    45
    Population
    Adults with metabolic dysfunction-associated steatotic liver disease; silymarin monotherapy versus no intervention or placebo, maximal follow-up; single trial

    Effect -8.3 mean difference, 95% CI -12.43 to -4.17

    Silymarin for adults with metabolic dysfunction-associated steatotic liver disease.2025PMID:4055256910.1002/14651858.CD015524.pub2Permalink

  • milk thistle extract (silymarin) — decreases alanine aminotransferase

    Evidence strength: very limited.Finding
    “Silymarin monotherapy versus no intervention or placebo may decrease ALT (MD -7.21 U/L, 95% CI -10.62 to -3.80; 6 trials, 409 participants; very low-certainty evidence) and GGT (MD -8.30 U/L, 95% CI -12.43 to -4.17; 1 trial, 45 participants; very low-certainty evidence), but the evidence is very uncertain.”
    Quoted verbatim from Silymarin for adults with metabolic dysfunction-associated steatotic liver disease..
    Study
    meta-analysis
    Participants
    409
    Population
    Adults with metabolic dysfunction-associated steatotic liver disease; silymarin monotherapy versus no intervention or placebo, maximal follow-up

    Effect -7.21 mean difference, 95% CI -10.62 to -3.8

    Silymarin for adults with metabolic dysfunction-associated steatotic liver disease.2025PMID:4055256910.1002/14651858.CD015524.pub2Permalink

What did not

1 finding

  • milk thistle extract (silymarin) — no detected effect on serious adverse event incidence

    Evidence strength: very limited.FindingNull result
    “The evidence suggests that silymarin monotherapy versus no intervention or placebo may result in little to no difference in serious adverse events (Peto OR 1.55, 95% CI 0.26 to 9.28; 4 trials, 304 participants; low-certainty evidence).”
    Quoted verbatim from Silymarin for adults with metabolic dysfunction-associated steatotic liver disease..
    Study
    meta-analysis
    Participants
    304
    Population
    Adults with metabolic dysfunction-associated steatotic liver disease; silymarin monotherapy versus no intervention or placebo

    Effect 1.55 odds ratio, 95% CI 0.26 to 9.28

    Silymarin for adults with metabolic dysfunction-associated steatotic liver disease.2025PMID:4055256910.1002/14651858.CD015524.pub2Permalink